More and more imaging researchers are starting to examine the potential of using fibroblast activation protein inhibitors (FAPI) to manage patients with suspected cardiovascular disease.
The BENEFIT-HF trial, scheduled to begin enrollment in the months ahead, could significantly increase the number of patients eligible for CVRx's Barostim therapy.
Shockwave Medical, now a part of Johnson & Johnson MedTech, sits at the top of the IVL market, but things are starting to get more competitive. Boston Scientific gained its own IVL system when it acquired Bolt Medical in 2025.
Gene-editing drugs have shown potential to treat a wide variety of diseases, and this will be one of the first in cardiovascular medicine to begin human trials.
Gene manipulation can revert the cardiomyocytes back to a fetal state, allowing them to regenerate. Researchers are now looking for drugs to mimic the effect.
The publication will include "pictorial essays, case reports and expert commentary for today’s practicing radiologists," the society announced Thursday.
Early detection of cardiac amyloidosis is leads to the best outcomes, but it is often missed until later stages. AI is being developed to help detect these patients earlier using ECG and echo.
Researchers explored data from 23 different studies, identifying a “positive and almost linear association” between alcohol consumption and hypertension.
A new study suggests sildenafil, known by its brand name Viagra, can improve cerebrovascular function and minimize the risk of cognitive impairment caused by small vessel disease.
Paul Zei, MD, discusses late-breaking data from the REAL-AF Registry, which looked at the short- and long-term outcomes of radiofrequency ablation in paroxysmal and persistent atrial fibrillation.
